Bronchopulmonary Dysplasia (BPD)

AyuVis is developing a new class of drug to treat bronchopulmonary dysplasia (BPD) with promising preclinical data. BPD is an orphan disease that affects 1.8M children worldwide annually and is growing and is considered one of the largest causes of neonatal death in US.

The unmet need for a solution

Bronchopulmonary dysplasia (BPD) is one of the most important sequels of preterm birth and one of the most serious chronic lung diseases in infancy. The etiology of BPD is multi-factorial and the prevalence is inversely related to birth weight and gestational age.

BPD.jpg
AVR-48_BPD-illustration-Biorender.png

Expected Benefits of AyuVis Compounds:

  • Increased patient survival rates

  • Reduced use of supplemental oxygen after discharge

  • Reduced lifetime respiratory problems 

  • Reduced hospital cost of care


AyuVis is developing a novel small immune-modulating agent that enhances the body’s ability to fight inflammation and restore lung function when administered intravenously. We anticipate that this will help reduce and prevent BPD in premature babies, and reduce their hospital stay.

The anti-inflammatory properties differ from current steroids in that they do not suppress normal immune function but appear to have a synergistic effect.